Kodiak Sciences Inc. (KOD) SEC Filings & Earnings Calls

Clinical trial risk: three Phase 3 readouts in H2 2026; failure could impair pipeline value.

“Topline data for DAYBREAK (Sep 2026) and PEAK (Dec 2026) pending.”

Cash burn rate high; runway only into 2027, potential need for dilutive financing.

“Cash $125.9M; net loss $65.6M/quarter; operations into 2027.”

Going concern risk

“The Company believes that the existing cash and cash equivalents may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q.” · word for word

Clinical trial failure risk

“The failure of pivotal studies to meet their primary efficacy endpoints may lead us to pause, change or discontinue development of product candidates based on our ABC Platform.” · word for word

Dilution risk

“If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates.” · word for word

Clinical-stage biotech with no approved products; dependent on successful trial outcomes and regulatory approvals.

“Kodiak is a clinical-stage company with no approved products; all revenue potential depends on regulatory approval of pipeline candidates.”

Cash runway only into 2027; may require additional financing if trials are delayed or extended.

“We believe that our current cash and cash equivalents will support our current and planned operations into 2027.” · word for word

Competitive landscape in wet AMD and diabetic retinopathy; multiple approved therapies exist.

“Zenkuda and KSI-501 target wet AMD and diabetic retinopathy, markets with established anti-VEGF therapies.”

Going concern risk - cash may not last 12 months

“The Company believes that the existing cash and cash equivalents may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q. As a result, there is substantial doubt regarding the Company's ability to continue as a going concern.” · word for word

Clinical trial failure risk

“The failure of pivotal studies to meet their primary efficacy endpoints may lead us to pause, change or discontinue development of product candidates based on our ABC Platform.” · word for word

No approved products or revenue

“We have never generated any revenue from product sales, and we may never generate revenue or be profitable.” · word for word

Clinical trial failure risk

“the risk that the completed Phase 3 studies for Zenkuda may not be sufficient to support a BLA submission or approval in diabetic retinopathy, retinal vein occlusion or wet AMD” · word for word

Regulatory approval risk

“the risk that a BLA for tarcocimab tedromer or any other product candidate may not be accepted by, or receive approval from, the FDA or foreign regulatory agencies when expected or at all” · word for word

Capital availability risk

“the risk that sufficient capital may not be available as expected, or at all, to complete the development of any products” · word for word

Stock price volatility / LTPIP value risk

“All of the LTPIP options granted to our NEOs have an exercise price of $88.21 per share and will provide no realizable value to our NEOs unless and until our stock price exceeds $88.21 per share.” · word for word

Clinical trial risks remain for ongoing studies (DAYBREAK, PEAK, PINNACLE).

“Topline data is expected in September 2026... Topline results from PEAK are expected in 4Q 2026 and for PINNACLE in 2Q 2027.” · word for word

No revenue yet; company is pre-commercial with significant R&D expenses.

“Financial results for the quarter and year ended December 31, 2025... (no revenue mentioned in excerpt).” · word for word

Going concern risk

“Our financial condition raises substantial doubt about our ability to continue as a going concern.” · word for word

No approved products / no revenue

“We have never generated any revenue from product sales, and we may never generate revenue or be profitable.” · word for word

Clinical trial failure risk

“The failure of pivotal studies to meet their primary efficacy endpoints may lead us to pause, change or discontinue development of other product candidates based on our ABC Platform.” · word for word

Dilution risk from equity offering

“Issuance of 8 million shares increases share count, diluting existing shareholders.”

Underwriting discount and expenses reduce net proceeds

“Underwriters purchased shares at $21.62 per share, a discount of $1.38 per share from the public price, plus other expenses.”

Going concern risk

“The Company believes that its existing cash and cash equivalents may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q. As a result, there is substantial doubt regarding the Company's ability to continue as a going concern.” · word for word

Clinical trial failure risk

“The failure of pivotal studies of tarcocimab to meet their primary efficacy endpoints may lead us to pause, change or discontinue development of other product candidates based on our ABC Platform.” · word for word

Financing risk

“If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates.” · word for word

Regulatory approval risk

“The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.” · word for word

Competition risk

“We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may retain their market share with existing drugs, or achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours.” · word for word